FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
29/06/2026 20:00
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports June 29 (Reuters) - The U.S. Food and Drug Administration has selected Eli Lilly LLY.N and Regeneron REGN.O, among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement